Crossmark

Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study

Crossref DOI link: https://doi.org/10.1016/j.ad.2024.08.014

Published Print: 2025-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ceravalls, J.

Giménez-Arnau, A.M.

Expósito-Serrano, V.

Fernández Chico, N.

Lara Moya, A.

Bielsa, I.

Ribó, P.

Mascaró-Hereza, B.

Bonfill-Ortí, M.

Spertino, J.

Serra, E.

Baliu-Piqué, C.

Melé-Ninot, G.
License Information

Text and Data Mining valid from 2025-07-01

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-02-27
More Information

This article is maintained by: Elsevier

Article Title: Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2024.08.014

Content Type: article

Copyright: © 2025 AEDV. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below